2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

T47D cells

" in MedChemExpress (MCE) Product Catalog:

38

Inhibitors & Agonists

2

Peptides

7

Natural
Products

1

Isotope-Labeled Compounds

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N4010
    Iriflophenone

    		Others Cancer
    Iriflophenone, isolated from Aquilaria sinensis, stimulates MCF-7 and T-47D human breast cancer cells proliferation .
    Iriflophenone
  • HY-125443
    Lucialdehyde A

    		Others Cancer
    Lucialdehydes A is a lanostante-type triterpene aldehydes, isolated from the fruiting bodies of Ganoderma lucidum. Lucialdehydes A shows cytotoxic effects on tumor cells, including Lewis lung carcinoma (LLC), T-47D, Sarcoma 180, and Meth-A tumor cell lines .
    Lucialdehyde A
  • HY-146087
    Autophagy inducer 4

    		Autophagy Cancer
    Autophagy inducer 4 is a Magnolol-based Mannich base derivatives, which can be used as an anticancer agent. Autophagy inducer 4 suppresses cancer cells via inducing autophagy. Autophagy inducer 4 has 76-fold improvement in cytotoxicity against T47D cells compared with Magnolol. Autophagy inducer 4 also possesses suppressive effects on migration of T47D and Hela cancer cells .
    Autophagy inducer 4
  • HY-155231
    Neutrophil elastase inhibitor 4

    		Elastase Cancer
    Neutrophil elastase inhibitor 4 (compound 4f) is a competitive human neutrophil elastase (HNE) inhibitor (IC50: 42.30 nM, Ki: 8.04 nM). Neutrophil elastase inhibitor 4 induces T47D cell apoptosis. Neutrophil elastase inhibitor 4 inhibits cell proliferation with IC50s of 21.25, 34.17, 29.93, 99.11 nM for T47D, RPMI 8226, A549, and HSF cells .
    Neutrophil elastase inhibitor 4
  • HY-153932
    NR-7h

    		PROTACs p38 MAPK Cancer
    NR-7h is a potent and selective p38α and p38β degrader with DC50 values of 24 nM and 27.2 nM for p38α in T47D, MB-MDA-231 cells, respectively .
    NR-7h
  • HY-155197
    ER degrader 7

    		Microtubule/Tubulin Estrogen Receptor/ERR Cancer
    ER degrader 7 (Compound 35t) is an ERα and ERβ degrader. ER degrader 7 inhibits tubulin polymerization. ER degrader 7 inhibits cell viability with IC50s of 0.06, 2.56, 15.84, 1.59, 1.67, 1.37 μM for MCF-7, T47D, MCF-10A, LCC2, T47D D538G, and T47D Y537S cells respectively. ER degrader 7 also inhibits breast cancer tumor growth .
    ER degrader 7
  • HY-151120
    Anticancer agent 79

    		Others Cancer
    Anticancer agent 79 (compound 3d) shows good anti-breast cancer activity. Anticancer agent 79 shows good cytotoxic activity in T47-D cells, with an IC50 of 13.64 ± 0.26 μM .
    Anticancer agent 79
  • HY-125664
    Lucialdehyde B

    		Antibiotic Cancer
    Lucialdehyde B is a tetracyclic triterpene isolated from the substrates of Ganoderma lucidum with antiviral and cytotoxic activities. Lucialdehyde B has cytotoxic effects against Lewis lung cancer (LLC), T-47D, Sarcoma 180 and Meth-A tumor cell lines .
    Lucialdehyde B
  • HY-106297
    Tosagestin

    Org 30659

    		 Others Metabolic Disease Cancer
    Tosagestin(Org 30659) is a 19-nortestosterone–derived progestagen. Tosagestinsuppresses ovarian function to a level sufficient to inhibit ovulation. Tosagestininhibits cell growth in T47D-S cells .
    Tosagestin
  • HY-150543
    Steroid sulfatase-IN-3

    		Steroid Sulfatase Cancer
    Steroid sulfatase-IN-3 (compound 1q) is a potent STS (Steroid sulfatase) inhibitor, with an IC50 of 25.8 nM. Steroid sulfatase-IN-3 shows antiproliferative activity against T-47D estrogen-dependent breast cancer cells, with an IC50 of 1.04 µM .
    Steroid sulfatase-IN-3
  • HY-155233
    Steroid sulfatase-IN-5

    		Steroid Sulfatase Cancer
    Steroid sulfatase-IN-5 (compound 10b) is a steroid sulfatase (STS) inhibitor (IC50: 0.32 nM). Steroid sulfatase-IN-5 inhibits T-47D cell proliferation with an IC50 of 35.7 μM. Steroid sulfatase-IN-5 can be used for research of breast cancer .
    Steroid sulfatase-IN-5
  • HY-160282
    PI3K-IN-49

    		PI3K Cancer
    PI3K-IN-49 is a potent PI3K inhibitor. PI3K-IN-49 shows antiproliferative activity for Avg T-47D and Avg SKBR3 cells (WO2023239710A1; example 29) .
    PI3K-IN-49
  • HY-N13118
    Sinopodophylline B

    		Others Cancer
    Sinopodophylline B (compound 2) is a flavonoid glycoside compound that is cytotoxic to breast cancer cells. For example, the IC50 of Sinopodophylline B is 1.5 μM (T47D) and 44.2 μM (MDA-MB-231), respectively .
    Sinopodophylline B
  • HY-157151
    iPRMT1

    		Histone Methyltransferase Cancer
    iPRMT1 is a potent and selective PRMT1 inhibitor for breast cancer research. iPRMT1 inhibits breast cancer cell growth in vitro and in vivo with EC50 values of 90, 70, and 9 nM in MCF7, T47D, and MDA-MB-231 cells, respectively .
    iPRMT1
  • HY-129578
    Asperphenamate

    		Autophagy Cathepsin Infection Inflammation/Immunology Cancer
    Asperphenamate, a fungal metabolite of Aspergillus flatiipes with anti-cancer effect, exhibits IC50 values of 92.3 μM, 96.5 μM and 97.9 μM in T47D, MDA-MB-231 and HL-60 cells, respectively .
    Asperphenamate
  • HY-124053
    BRD2492

    		HDAC Cancer
    BRD2492 (compound 6d) is a potent, selective HDAC1 and HDAC2 inhibitor with IC50s of 13.2 nM and 77.2 nM, respecrtively. BRD2492 exhibits >100-fold selectivity for HDAC1/2 over selectivity over HDAC3 and HDAC6. BRD2492 inhibits breast cancer cell lines growth with IC50s of 1.01 μM and 11.13 μM for T-47D and MCF-7 cells, respectively .
    BRD2492
  • HY-163119
    Pim-1 kinase inhibitor 9

    		Pim Cancer
    Pim-1 kinase inhibitor 9 (compound 8b) is a selective inhibitor against Pim-1 kinase with IC50 value of 0.24 µM. Pim-1 kinase inhibitor 9 inhibits cell cycle of T47D at S phase. Pim-1 kinase inhibitor 9 reveals antitumor activity .
    Pim-1 kinase inhibitor 9
  • HY-128600
    ERD-308
    1 Publications Verification

    		 PROTACs Estrogen Receptor/ERR Cancer
    ERD-308 is a highly potent von Hippel-Lindau-based PROTAC degrader of estrogen receptor (ER) for ER positive breast cancer treatment. ERD-308 induces >95% of ER degradation at concentrations as low as 5 nM in both cell lines (DC50 (concentration causing 50% of protein degradation) of 0.17 nM and 0.43 nM in MCF-7 and T47D ER+ cells, respectively) .
    ERD-308
  • HY-162751
    Anticancer agent 249

    		HSP Apoptosis Cancer
    Anticancer agent 249 (Compound 89) is an inhibitor for Hsp90β with IC50 of 16.5 μM in PC3MM2 cell. Anticancer agent 249 inhibits proliferation of cancer cells MCF-7, T47D, MDA-MB-231, MDA-MB-468 and SKBr3 with IC50 of 1.8-5.3 μM. Anticancer agent 249 induces apoptosis in MDA-MB-231. Anticancer agent 249 exhibits antitumor efficacy in mice .
    Anticancer agent 249
  • HY-169019
    XJTU-L453

    		PI3K Apoptosis Cancer
    XJTU-L453 is a PI3Kα inhibitor with an IC50 value of 0.4 nM. XJTU-L453 can inhibit the proliferation of breast cancer cell lines T47D and MCF7, with IC50 values of 0.2 μM and 0.5 μM, respectively. XJTU-L453 can inhibit the PI3K pathway, induce cell cycle arrest, and trigger cell apoptosis (apoptosis). XJTU-L453 also has antitumor activity in MCF7 xenograft mice .
    XJTU-L453
  • HY-P10393
    ERα17p

    ERα (295-311)

    		 Apoptosis Cancer
    ERα17p (ERα 295-311) is the epitope of the CaM binding site on the estrogen receptor α (ER), which interacts with calmodulin (CaM) in a calcium-dependent manner. ERα17p regulates the migration of cancer cells MCF-7, SK-BR-3, T47D, and MDA-MB-231 through Rho/ROCK and PI3K/Akt signaling pathways. ERα17p inhibits proliferations of breast cancer cells, induces apoptosis, and inhibits tumor growth in mouse models .
    ERα17p
  • HY-161995
    FGFR1/VEGFR2-IN-2

    		Apoptosis Necroptosis FGFR VEGFR PDGFR Cancer
    FGFR1/VEGFR2-IN-2 (compound 6l) is a VEGFR2/FGFR1 dual inhibitor. The IC50 values for VEGFR2 and FGFR1 are 0.025 µM and 0.026 µM respectively, and for EGFR and PDGFR-β, the IC50 values are 0.106 µM and 0.077 µM. FGFR1/VEGFR2-IN-2 showes significant anti-cancer activity (GI=60.38%) on NCI-60 cell line, with an IC50 of 8.51 µM in T-47D cell line and anti-migration. FGFR1/VEGFR2-IN-2 acts to arrest cells in the G1 phase and promote apoptosis and necrosis; the IC50 for MCF-7 cell line exceeds 100 µM, and the IC50 for MDA-MB-231 is 69.17 µM, non-toxic to normal cells .
    FGFR1/VEGFR2-IN-2
  • HY-123163
    JNJ-1250132

    RWJ-66826; RTI-6617-003

    		 Progesterone Receptor Glucocorticoid Receptor Androgen Receptor Estrogen Receptor/ERR Endocrinology Cancer
    JNJ-1250132 (RWJ-66826) is an orally active and potent steroidal progesterone receptor (PR) antagonist, with an IC50 of 1.3 nM. JNJ-1250132 inhibits binding of the receptor to DNA in vitro. JNJ-1250132 is a potent competitive inhibitor of binding to the human glucocorticoid receptor (GR) (IC50=0.50 nM) and the rat androgen receptor (AR) (IC50=5.6 nM), and was a weak inhibitor of binding to human Estrogen receptor (ER) (IC50 >3000 nM) .
    JNJ-1250132
  • HY-162529
    CDK4/6-IN-19

    		CDK Cancer
    CDK4/6-IN-19 (Compound II-7) is a CDK4/CDK6 inhibitor with IC50 values ​​of 0.2, 5.0 nM, respectively. CDK4/6-IN-19 also inhibits cell proliferation and can be used in cancer research .
    CDK4/6-IN-19
  • HY-162530
    CDK4/6-IN-20

    		CDK Cancer
    CDK4/6-IN-20 (Compound II-5) is a CDK4/CDK6 inhibitor with IC50 values ​​of 1.9, 14.2 nM, respectively. CDK4/6-IN-20 also inhibits cell proliferation and can be used in cancer research .
    CDK4/6-IN-20
  • HY-B0648
    Medroxyprogesterone
    5+ Cited Publications

    17α-Hydroxy-6α-methylprogesterone; U8840

    		 Progesterone Receptor Endocrinology Cancer
    Medroxyprogesterone (17α-Hydroxy-6α-methylprogesterone) is a synthetic human variant of progesterone that is a progesterone receptor agonist with oral activity. Medroxyprogesterone can induce cell proliferation through the PI3K/Akt signaling pathway. Medroxyprogesterone has an inhibitory effect on atherosclerosis in mice. The progesterone agonist activity of Medroxyprogesterone is less effective than Medroxyprogesterone acetate (HY-B0469) .
    Medroxyprogesterone
  • HY-113293B
    Estrone sulfate sodium
    1 Publications Verification

    		 Estrogen Receptor/ERR Endogenous Metabolite Cancer
    Estrone sulfate, a biologically inactive form of estrogen, is a major circulating plasma estrogen that is converted into the biologically active estrogen, estrone (E1) by steroid sulfatase (STS). Estrone sulfate can be used for the research of breast cancer .
    Estrone sulfate sodium
  • HY-151199
    Steroid sulfatase/17β-HSD1-IN-1

    		Steroid Sulfatase Endocrinology Cancer
    Steroid sulfatase/17β-HSD1-IN-1 is a potent steroid sulfatase and 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitor with an IC50 value of 28 nM for cellular human steroid sulfatase. Steroid sulfatase/17β-HSD1-IN-1 can be used to research estrogen-dependent diseases .
    Steroid sulfatase/17β-HSD1-IN-1
  • HY-P2965
    L-Lysine α-oxidase

    		Others Cancer
    L-Lysine α-oxidase is a potent anticancer agent. L-Lysine α-oxidase also a L-amino acid oxidase, deaminates L-lysine with the yield of H2O2, ammonia, and α-keto-ε-aminocaproate. L-Lysine α-oxidase shows cytotoxicity and anticancer activity .
    L-Lysine α-oxidase
  • HY-19822A
    Elacestrant dihydrochloride
    Maximum Cited Publications
    10 Publications Verification

    RAD1901 dihydrochloride

    		 Estrogen Receptor/ERR Cancer
    Elacestrant (RAD1901) dihydrochloride is an orally available and selective estrogen receptor degrader (SERD) with IC50s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant dihydrochloride also can inhibit growth of ER + breast cancer cell lines in vitro and in vivo .
    Elacestrant dihydrochloride
  • HY-19822
    Elacestrant
    Maximum Cited Publications
    10 Publications Verification

    RAD1901

    		 Estrogen Receptor/ERR Cancer
    Elacestrant (RAD1901) is an orally available and selective estrogen receptor degrader (SERD) with IC50s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant also can inhibit growth of ER + breast cancer cell lines in vitro and in vivo .
    Elacestrant
  • HY-19822S2
    Elacestrant-d10

    RAD1901-d10

    		 Estrogen Receptor/ERR Isotope-Labeled Compounds Cancer
    Elacestrant-d10 is the deuterium labeled of Elacestrant (HY-19822). Elacestrant is an orally available and selective estrogen receptor degrader (SERD) with IC50s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant also inhibits growth of ER + breast cancer cell lines in vitro and in vivo .
    Elacestrant-d10
  • HY-125916
    Pseurotin A

    		Endogenous Metabolite Cancer
    Pseurotin A, a secondary metabolite of Aspergillus and other fungi, is a competitive inhibitor of chitin synthase and a neuritogenic agent. Pseurotin A inhibits IgE production (IC50=3.6 μM). Antitumor activity .
    Pseurotin A
  • HY-118257
    Org-31710

    		Progesterone Receptor Endocrinology Cancer
    Org-31710 is a specific progesterone receptor (PR) inhibitor. Org-31710 shows antiprogestational effect. Org 31710 abolishes the folic acid (HY-16637)-regulated proliferation and migration in PR positive cancer cell lines. Org 31710 abolishes the folic acid-increased the levels of p-PRA, p-PRB, and p-cSrcY416 .
    Org-31710
  • HY-103302
    SUN B8155

    		CGRP Receptor Endocrinology
    SUN B8155, a non-peptide agonist of calcitonin (CT) receptor, selectively mimics the biological actions of calcitonin. Calcitonin, a 32-amino acid peptide hormone secreted mainly from the thyroid gland, plays an important role in maintaining bone homeostasis .
    SUN B8155
  • HY-119995
    Chloropyramine

    		Apoptosis Histamine Receptor Cardiovascular Disease Cancer
    Chloropyramine is competitive reversible H1 receptor antagonist. Chloropyramine also has anti-tumour activity in breast cancer. Chloropyramine can be used for the research of allergic conditions, such as conjunctivitis and bronchial asthma .
    Chloropyramine
  • HY-120234
    Z-LLNle-CHO

    Z-Leu-Leu-Nle-CHO; GSII

    		 γ-secretase Proteasome Apoptosis Cancer
    Z-LLNle-CHO (Z-Leu-Leu-Nle-CHO) is a γ-secretase inhibitor I. Z-LLNle-CHO induces caspase and ROS-dependent apoptosis by blocking the Akt-mediated pro-survival pathway. Z-LLNle-CHO can be used in cancer research, such as breast cancer and leukaemia .
    Z-LLNle-CHO
  • HY-U00447
    PK11000

    		MDM-2/p53 DNA Alkylator/Crosslinker Cancer
    PK11000 is an alkylating agent, and stabilizes the DNA-binding domain of both WT and mutant p53 proteins by covalent cysteine modification without compromising DNA binding. PK11000 has anti-tumor activities .
    PK11000

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: